BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1025 related articles for article (PubMed ID: 8052972)

  • 1. Platelet deposition induced by severely damaged vessel wall is inhibited by a boroarginine synthetic peptide with antithrombin activity.
    Badimon JJ; Weng D; Chesebro JH; Fuster V; Badimon L
    Thromb Haemost; 1994 Apr; 71(4):511-6. PubMed ID: 8052972
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Thrombus formation and platelet-vessel wall interaction in the nephrotic syndrome under flow conditions.
    Zwaginga JJ; Koomans HA; Sixma JJ; Rabelink TJ
    J Clin Invest; 1994 Jan; 93(1):204-11. PubMed ID: 8282789
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antithrombotic effects of the novel inhibitor of thrombin-induced offtelet aggregation and thrombus formation, 3-[2-[1,1':2',1"]-terphenyl-4'-yl)ethyl]phenoxyacetic acid.
    Miyamae T; Hashizume H; Ogawa T; Okayama T; Nukui E; Oshima K; Morikawa T; Hagiwara M
    Arzneimittelforschung; 1997 Jan; 47(1):13-8. PubMed ID: 9037437
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A sudden increase in plasma epinephrine levels transiently enhances platelet deposition on severely damaged arterial wall--studies in a porcine model.
    Badimon L; Martínez-González J; Royo T; Lassila R; Badimon JJ
    Thromb Haemost; 1999 Dec; 82(6):1736-42. PubMed ID: 10613663
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antithrombotic properties of pravastatin reducing intra-thrombus fibrin deposition under high shear blood flow conditions.
    Hamada M; Sugimoto M; Matsui H; Mizuno T; Shida Y; Doi M; Fukushima H; Nishio K; Yoshioka A; Shima M
    Thromb Haemost; 2011 Feb; 105(2):313-20. PubMed ID: 21136018
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Modulation of procoagulant activity of extracellular endothelial matrix by anti-tissue factor antibody and the synthetic peptide Arg-Gly-Asp-Val. Experiments with flowing non-anticoagulated human blood.
    Salatti JA; Anton P; Nemerson Y; Sakariassen KS
    Blood Coagul Fibrinolysis; 1993 Dec; 4(6):881-90. PubMed ID: 8148480
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antithrombotic effects of MK-0852, a platelet fibrinogen receptor antagonist, in canine models of thrombosis.
    Ramjit DR; Lynch JJ; Sitko GR; Mellott MJ; Holahan MA; Stabilito II; Stranieri MT; Zhang G; Lynch RJ; Manno PD
    J Pharmacol Exp Ther; 1993 Sep; 266(3):1501-11. PubMed ID: 8371153
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Experimental thrombosis on a collagen coated arterioarterial shunt in rats: a pharmacological model to study antithrombotic agents inhibiting thrombin formation and platelet deposition.
    Freund M; Mantz F; Nicolini P; Gachet C; Mulvihill J; Meyer L; Beretz A; Cazenave JP
    Thromb Haemost; 1993 May; 69(5):515-21. PubMed ID: 8322274
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The in-vitro effect of tirofiban, glycoprotein IIb/IIIa antagonist, on various responses of porcine blood platelets.
    Ciborowski M; Tomasiak M; Rusak T; Winnicka K; Dobrzycki S
    Blood Coagul Fibrinolysis; 2008 Sep; 19(6):557-67. PubMed ID: 18685439
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of SR121566A, a potent GP IIb-IIIa antagonist on platelet-mediated thrombin generation in vitro and in vivo.
    Herault JP; Peyrou V; Savi P; Bernat A; Herbert JM
    Thromb Haemost; 1998 Feb; 79(2):383-8. PubMed ID: 9493595
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HN-11500--a novel thromboxane A2 receptor antagonist with antithrombotic activity in humans at arterial blood flow conditions.
    Roald HE; Barstad RM; Engen A; Kierulf P; Skjørten F; Sakariassen KS
    Thromb Haemost; 1994 Jan; 71(1):103-9. PubMed ID: 8165627
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Protein disulphide isomerase-mediated LA419- NO release provides additional antithrombotic effects to the blockade of the ADP receptor.
    Vilahur G; Pena E; Padró T; Badimon L
    Thromb Haemost; 2007 Apr; 97(4):650-7. PubMed ID: 17393029
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Thrombin regulation of platelet interaction with damaged vessel wall and isolated collagen type I at arterial flow conditions in a porcine model: effects of hirudins, heparin, and calcium chelation.
    Badimon L; Badimon JJ; Lassila R; Heras M; Chesebro JH; Fuster V
    Blood; 1991 Jul; 78(2):423-34. PubMed ID: 2070078
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of platelet recruitment to arterial lesions by predeposition of platelets containing encapsulated iloprost.
    Pfliegler G; el-Gamal B; Badimon JJ; Badimon L; Crawford N
    Thromb Haemost; 1994 Oct; 72(4):604-10. PubMed ID: 7533337
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Peptides as inhibitors of thrombin coagulation activity and of thrombocyte aggregation].
    Pastorova VE; Liapina LA; Cherkasova KA; Ashmarin IP
    Usp Fiziol Nauk; 1999; 30(2):80-91. PubMed ID: 10420478
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of a novel platelet nitric oxide donor (LA816), aspirin, clopidogrel, and combined therapy in inhibiting flow- and lesion-dependent thrombosis in the porcine ex vivo model.
    Vilahur G; Segalés E; Salas E; Badimon L
    Circulation; 2004 Sep; 110(12):1686-93. PubMed ID: 15381660
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pretreatment of human platelets with plasmin inhibits responses to thrombin, but potentiates responses to low concentrations of aggregating agents, including the thrombin receptor activating peptide, SFLLRN.
    Kinlough-Rathbone RL; Perry DW; Rand ML; Packham MA
    Thromb Haemost; 1997 Apr; 77(4):741-7. PubMed ID: 9134653
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A new method for quantifying platelet deposition in flowing native blood in an ex vivo model of human thrombogenesis.
    Bossavy JP; Sakariassen KS; Barret A; Boneu B; Cadroy Y
    Thromb Haemost; 1998 Jan; 79(1):162-8. PubMed ID: 9459343
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biological properties of a specific Galpha q/11 inhibitor, YM-254890, on platelet functions and thrombus formation under high-shear stress.
    Uemura T; Kawasaki T; Taniguchi M; Moritani Y; Hayashi K; Saito T; Takasaki J; Uchida W; Miyata K
    Br J Pharmacol; 2006 May; 148(1):61-9. PubMed ID: 16520742
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Platelet-vessel wall interactions in thrombosis and restenosis role of von Willebrand factor.
    Hoylaerts MF
    Verh K Acad Geneeskd Belg; 1997; 59(3):161-83. PubMed ID: 9490916
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 52.